Mechanism of Action of Ocrelizumab in Multiple Sclerosis
NCT03344094
·
clinicaltrials.gov ↗
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis
Immune System Diseases
Interventions
DRUG:
ocrelizumab
Sponsor
University of Chicago